INVEST revisited: Review of findings from the International Verapamil SR-Trandolapril Study

Rhonda M. Cooper-DeHoff; Eileen M. Handberg; Giuseppe Mancia; Qian Zhou; Annette Champion; Udo F. Legler; Carl J. Pepine

doi:10.1586/erc.09.102

INVEST revisited: Review of findings from the International Verapamil SR-Trandolapril Study

Rhonda M. Cooper-DeHoff, Eileen M. Handberg, Giuseppe Mancia, Qian Zhou, Annette Champion, Udo F. Legler, Carl J. Pepine

Fondazione Istituto Auxologico Italiano

Research output: Contribution to journal › Article › peer-review

Abstract

The International Verapamil SR-Trandolapril Study (INVEST), a randomized trial of 22,576 predominantly elderly patients with an average 2.7-year follow-up, compared a calcium antagonist-led strategy (verapamil SR plus trandolapril) with a β-blocker-led strategy (atenolol plus hydrochlorothiazide) for hypertension treatment and prevention of cardiovascular outcomes in coronary artery disease patients. Patients received individualized dose and drug titration following a flexible, multi-drug, guideline-based treatment algorithm, with the objective of achieving optimal blood pressure (BP) control individualized for comorbidities (e.g., diabetes). The primary outcome (PO) was first occurrence of death (all-cause), nonfatal myocardial infarction or nonfatal stroke. The strategies resulted in significant and very similar BP reduction, with approximately 70% of patients in both strategies achieving BP control (

Original language	English
Pages (from-to)	1329-1340
Number of pages	12
Journal	Expert Review of Cardiovascular Therapy
Volume	7
Issue number	11
DOIs	https://doi.org/10.1586/erc.09.102
Publication status	Published - Nov 2009

Keywords

Atenolol
Coronary artery disease
Hydrochlorothiazide
Hypertension
INVEST
New-onset diabetes
Trandolapril
Verapamil SR

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Internal Medicine

Access to Document

10.1586/erc.09.102

Cite this

@article{1f7c50d358dd46eaa567e7982200d455,

title = "INVEST revisited: Review of findings from the International Verapamil SR-Trandolapril Study",

abstract = "The International Verapamil SR-Trandolapril Study (INVEST), a randomized trial of 22,576 predominantly elderly patients with an average 2.7-year follow-up, compared a calcium antagonist-led strategy (verapamil SR plus trandolapril) with a β-blocker-led strategy (atenolol plus hydrochlorothiazide) for hypertension treatment and prevention of cardiovascular outcomes in coronary artery disease patients. Patients received individualized dose and drug titration following a flexible, multi-drug, guideline-based treatment algorithm, with the objective of achieving optimal blood pressure (BP) control individualized for comorbidities (e.g., diabetes). The primary outcome (PO) was first occurrence of death (all-cause), nonfatal myocardial infarction or nonfatal stroke. The strategies resulted in significant and very similar BP reduction, with approximately 70% of patients in both strategies achieving BP control (",

keywords = "Atenolol, Coronary artery disease, Hydrochlorothiazide, Hypertension, INVEST, New-onset diabetes, Trandolapril, Verapamil SR",

author = "Cooper-DeHoff, {Rhonda M.} and Handberg, {Eileen M.} and Giuseppe Mancia and Qian Zhou and Annette Champion and Legler, {Udo F.} and Pepine, {Carl J.}",

year = "2009",

month = nov,

doi = "10.1586/erc.09.102",

language = "English",

volume = "7",

pages = "1329--1340",

journal = "Expert Review of Cardiovascular Therapy",

issn = "1477-9072",

publisher = "Expert Reviews Ltd.",

number = "11",

}

TY - JOUR

T1 - INVEST revisited

T2 - Review of findings from the International Verapamil SR-Trandolapril Study

AU - Cooper-DeHoff, Rhonda M.

AU - Handberg, Eileen M.

AU - Mancia, Giuseppe

AU - Zhou, Qian

AU - Champion, Annette

AU - Legler, Udo F.

AU - Pepine, Carl J.

PY - 2009/11

Y1 - 2009/11

N2 - The International Verapamil SR-Trandolapril Study (INVEST), a randomized trial of 22,576 predominantly elderly patients with an average 2.7-year follow-up, compared a calcium antagonist-led strategy (verapamil SR plus trandolapril) with a β-blocker-led strategy (atenolol plus hydrochlorothiazide) for hypertension treatment and prevention of cardiovascular outcomes in coronary artery disease patients. Patients received individualized dose and drug titration following a flexible, multi-drug, guideline-based treatment algorithm, with the objective of achieving optimal blood pressure (BP) control individualized for comorbidities (e.g., diabetes). The primary outcome (PO) was first occurrence of death (all-cause), nonfatal myocardial infarction or nonfatal stroke. The strategies resulted in significant and very similar BP reduction, with approximately 70% of patients in both strategies achieving BP control (

AB - The International Verapamil SR-Trandolapril Study (INVEST), a randomized trial of 22,576 predominantly elderly patients with an average 2.7-year follow-up, compared a calcium antagonist-led strategy (verapamil SR plus trandolapril) with a β-blocker-led strategy (atenolol plus hydrochlorothiazide) for hypertension treatment and prevention of cardiovascular outcomes in coronary artery disease patients. Patients received individualized dose and drug titration following a flexible, multi-drug, guideline-based treatment algorithm, with the objective of achieving optimal blood pressure (BP) control individualized for comorbidities (e.g., diabetes). The primary outcome (PO) was first occurrence of death (all-cause), nonfatal myocardial infarction or nonfatal stroke. The strategies resulted in significant and very similar BP reduction, with approximately 70% of patients in both strategies achieving BP control (

KW - Atenolol

KW - Coronary artery disease

KW - Hydrochlorothiazide

KW - Hypertension

KW - INVEST

KW - New-onset diabetes

KW - Trandolapril

KW - Verapamil SR

UR - http://www.scopus.com/inward/record.url?scp=73349138608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349138608&partnerID=8YFLogxK

U2 - 10.1586/erc.09.102

DO - 10.1586/erc.09.102

M3 - Article

C2 - 19900016

AN - SCOPUS:73349138608

SN - 1477-9072

VL - 7

SP - 1329

EP - 1340

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

IS - 11

ER -

INVEST revisited: Review of findings from the International Verapamil SR-Trandolapril Study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this